Updated notice to holders of ADSs regarding termination of Deposit Agreement
20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery and development of innovative peptide-based medicines, hereby provides notice to holders of American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs) representing deposited ordinary shares of the Company regarding termination of the Deposit Agreement (the Deposit Agreement), dated August 8, 2017, among the Company, The Bank of New York Mellon, as depositary (the the Depositary), and Owners and ADR Holders (ADR Holders).
- 20 04 50 78), a Copenhagen-headquartered biotechnology company focused on the discovery and development of innovative peptide-based medicines, hereby provides notice to holders of American Depositary Shares (ADSs) evidenced by American Depositary Receipts (ADRs) representing deposited ordinary shares of the Company regarding termination of the Deposit Agreement (the Deposit Agreement), dated August 8, 2017, among the Company, The Bank of New York Mellon, as depositary (the the Depositary), and Owners and ADR Holders (ADR Holders).
- On August 3, 2022, ADR Holders were notified by the Depositary that the Depositary will terminate the Deposit Agreement effective at 5:00 PM (Eastern Time) on November 2, 2022.
- Under the terms of the Deposit Agreement, ADR Holders have until at least November 7, 2022, to surrender their Zealand ADRs for delivery of the underlying shares.
- Subsequent to November 7, 2022, under the terms of the Deposit Agreement, the Depositary may attempt to sell the underlying shares.